Identifying gaps in respiratory syncytial virus disease epidemiology in the United States Prior to the introduction of vaccines

Lindsay Kim, Brian Rha, Jon S. Abramson, Larry J. Anderson, Carrie L. Byington, Grace L. Chen, John Devincenzo, Kathryn M. Edwards, Janet A. Englund, Ann R. Falsey, Marie R. Griffin, Ruth A. Karron, Karen G. Martin, H. Cody Meissner, Flor M. Munoz, Andrew T. Pavia, Pedro A. Piedra, William Schaffner, Eric A.F. Simões, Rosalyn SingletonH. Keipp Talbot, Edward E. Walsh, Jane R. Zucker, Susan I. Gerber

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Respiratory syncytial virus (RSV) causes lower respiratory tract illness frequently. No effective antivirals or vaccines for RSV are approved for use in the United States; however, there are at least 50 vaccines and monoclonal antibody products in development, with those targeting older adults and pregnant women (to protect young infants) in phase 2 and 3 clinical trials. Unanswered questions regarding RSV epidemiology need to be identified and addressed prior to RSV vaccine introduction to guide the measurement of impact and future recommendations. The Centers for Disease Control and Prevention (CDC) convened a technical consultation to gather input from external subject matter experts on their individual perspectives regarding evidence gaps in current RSV epidemiology in the United States, potential studies and surveillance platforms needed to fill these gaps, and prioritizing efforts. Participants articulated their individual views, and CDC staff synthesized individuals' input into this report.

Original languageEnglish (US)
Pages (from-to)1020-1025
Number of pages6
JournalClinical Infectious Diseases
Volume65
Issue number6
DOIs
StatePublished - Sep 15 2017

Keywords

  • Epidemiology
  • Monoclonal antibody
  • Respiratory syncytial virus
  • Vaccine
  • Vaccine impact

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Identifying gaps in respiratory syncytial virus disease epidemiology in the United States Prior to the introduction of vaccines'. Together they form a unique fingerprint.

Cite this